

REVIEW

Active discopathy: a clinical
realityMargaux Boisson,¹ Marie-Martine Lefèvre-Colau,^{1,2,3,4} François Rannou,^{1,2,5}
Christelle Nguyen^{1,2,5}

To cite: Boisson M, Lefèvre-Colau M-M, Rannou F, et al. Active discopathy: a clinical reality. *RMD Open* 2018;4:e000660. doi:10.1136/rmdopen-2018-000660

Received 3 February 2018
Revised 21 March 2018
Accepted 26 March 2018



¹AP-HP, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Hôpitaux Universitaires Paris Centre-Groupe Hospitalier Cochin, Paris, France

²Faculté de Médecine de Paris Descartes, Université Paris Descartes, Sorbonne Paris Cité, Paris, France

³ECaMO Team, INSERM UMR 1153, Centre de Recherche Épidémiologie et Statistique, Sorbonne Paris Cité, Paris, France

⁴Institut Fédératif de Recherche sur le Handicap, Paris, France

⁵Laboratoire de Pharmacologie, Toxicologie et Signalisation Cellulaire, Faculté des Sciences Fondamentales et Biomédicales, INSERM UMR 1124, UFR Biomédicale des Saints-Pères, Paris, France

Correspondence to

Dr Christelle Nguyen;
christelle.nguyen2@aphp.fr

ABSTRACT

In the late 1980s, the description by Modic and colleagues of elementary discovertebral changes detected on MRI (Modic classification) suggested for the first time a possible correlation between anatomical and clinical features in a subgroup of patients with non-specific chronic low back pain. Degenerative disc disease is frequent and usually asymptomatic, but Modic 1 changes in the vertebral endplates adjacent to a degenerated disc are associated with inflammatory-like chronic low back pain and low-grade local and systemic inflammation, which led to the concept of 'active discopathy'. Active discopathy shares some similarities with acute flares of peripheral osteoarthritis. Likewise, what triggers disc activation and how it self-limits remain unknown. A better understanding of mechanisms underlying disc activation and its self-limitation is of clinical relevance because it may enable the design of more targeted pharmacological and non-pharmacological interventions for the subgroup of patients with chronic low back pain and active discopathy. Here, we narratively review current disc-centred biomechanical and biochemical hypotheses of disc activation and discuss evidence of interactions with adverse personal and environmental factors.

INTRODUCTION

Non-specific low back pain (LBP) is the first cause of years lived with disability.¹ The aetiological diagnosis of LBP is challenging because a consistent anatomoclinical correlation is usually lacking. However, the development of lumbar MRI and studies of large cohorts of patients with LBP have allowed for isolating lesions involving the vertebral endplates adjacent to degenerative disc disease (DDD) that seem closely related to persistent painful symptoms.²⁻³ These lesions were classified in 1988 by Modic and colleagues: Modic 1 changes correspond to inflammatory signal of the vertebral endplates, Modic 2 to fatty signal and Modic 3 to fibrous signal.^{4,5}

As early as 1990, Revel and colleagues,⁶ on the basis of X-ray findings, reported that rapid intervertebral space narrowing $\geq 50\%$ in less than 2 years, in the absence of specific causes of disc disease, was associated with inflammatory-like LBP, which responded better to

Key messages**What is already known about this subject?**

- ▶ Active discopathy is a specific entity that associates clinical, biological and MRI signs of activity with degenerative disc disease.

What does this study add?

- ▶ The onset of active discopathy is unknown but is most likely multifactorial, involving both biomechanical and complex biochemical adverse factors in addition to genetic and individual predisposing factors.

How might this impact on clinical practice?

- ▶ Although local inflammation is currently the main therapeutic target, it may be only a late-stage marker of disc disease activation, and a better understanding of disc activation complex pathogenesis is needed to develop more comprehensive and long-term efficient treatments.

non-steroidal anti-inflammatory drugs than did other causes of non-specific LBP. The authors suggested that this imaging and clinical phenotype could be related to an 'active' process of discolysis and named it 'rapidly destructive intervertebral disc disease'.⁶ They further related this condition to Modic 1 changes.^{7,8} They also observed that the condition was associated with increased serum levels of inflammatory markers such as highly sensitive C-reactive protein⁹ and therefore might reflect an 'active discopathy'.⁷ The concept of active discopathy now encompasses clinical, biological and imaging features that reflect an 'activation' (ie, 'inflammatory flare') of a previously unremarkable DDD in a subgroup of patients with chronic LBP.¹⁰

Active discopathy shares some similarities with acute flares of peripheral osteoarthritis. Likewise, what triggers disc disease activation and how it self-limits remain unknown. A better understanding of mechanisms underlying disc disease activation and its self-limitation, with a specific focus on adverse

biomechanical and biochemical factors, could be of clinical relevance.¹¹ Here, we narratively review current disc-centred biomechanical and biochemical hypotheses of disc disease activation.

WHAT IS ACTIVE DISCOPATHY?

Degenerative disc disease

To understand active discopathy, we first describe 'non-active' disc disease, or DDD. At the macroscopic level, DDD affects the intervertebral disc and also the whole discovertebral complex.¹² It is characterised by a fibrillar structure of the *annulus fibrosus*, cracks of the *nucleus pulposus*, thinning and erosions of the cartilaginous vertebral endplates, marginal osteophytosis and loss of disc height.^{13 14} DDD results from an imbalance in intervertebral disc homeostasis with quantitative and qualitative changes affecting intervertebral disc cells and extracellular matrix as well as decreased water content that impair the biomechanics of the intervertebral disc. At the molecular level, DDD is associated with local inflammatory processes characterised by immunological stimulation, neovascularisation and neoinnervation, accelerated cartilaginous and bone remodelling, and changes in lipid and oxidative metabolism.¹⁵⁻¹⁸ At the MRI level, the most consistently reported signs of DDD are *nucleus pulposus* dehydration, decreased disc height, disc bulging or hernia.⁴ Pfirrmann and colleagues described five MRI grades of DDD.¹⁹ The first grade corresponds to a normal intervertebral disc, and higher grades correspond to DDD and have in common a hypointense signal in T2-weighted sequences of a homogenous *nucleus pulposus*, with no distinction between the *annulus fibrosus* and *nucleus pulposus*, and loss of intervertebral disc height.¹⁹ However, no consistent anatomoclinical correlation between DDD and LBP has been described.²⁰

Activation of DDD

MRI signs

In the late 1980s, Modic and colleagues described three elementary lesions corresponding to three MRI signal changes affecting the vertebral endplates adjacent to DDD detected on lumbar MRI of 474 patients with LBP⁵: a Modic 1 signal corresponds to a hypointense signal in T1-weighted MRI sequences and a hyperintense signal in T2-weighted sequences with contrast enhancement after gadolinium injection, indicating local inflammation. Histologically, fissures of the vertebral endplates are observed, with vascularised granulation tissue replacing the normal bone marrow as well as an increased number of osteoblasts and osteoclasts with a thickening of the bony spans, indicating bone remodelling. A Modic 2 signal corresponds to a hyperintense signal in T1 and T2-weighted MRI sequences, indicating fatty replacement of bone marrow. Histologically, cracks in vertebral endplates are observed with granulation tissue but not hypervascularisation. A Modic 3 signal corresponds to a hypointense signal in T1 and T2-weighted MRI

sequences, indicating bone sclerosis. The prevalence of Modic changes, whatever their type, ranges from 6% in asymptomatic patients to 43% in patients with LBP.³ Modic changes usually evolve over 1–3 years, from Modic 1 to Modic 2 (then Modic 3), which may reflect a dynamic healing process. However, many longitudinal studies have shown that this evolution is not linear and could be reversed in some cases, with reactivation of the disc disease over time.²¹⁻²⁴

Clinical signs

Patients with LBP and active discopathy usually report a flare of previously unremarkable LBP with inflammatory-like features. The influence of DDD activation and radiculopathy incidence has not been studied. First described by Revel and colleagues in the context of rapidly destructive intervertebral disc disease, an inflammatory LBP pattern associated with Modic 1 changes was confirmed by Rannou and colleagues in a cross-sectional study of 36 patients (12 with Modic 1 changes, 12 with Modic 2 changes and 12 with Modic 0 changes). Morning stiffness was longer and more often present in patients with Modic 1 than Modic 0 or 2 changes, and the worst painful moment was during late night and morning in all patients with Modic 1 changes. Discogenic pain was also more frequent in patients with Modic 1 than Modic 0 or 2 changes, including reproduction of the pain during Valsalva manoeuvres and exacerbation of pain in lumbar hyperextension. Despite this inflammatory LBP pattern, patients with LBP and active discopathy do not fulfil criteria for ankylosing spondylitis and criteria sets for inflammatory LBP.²⁵ Other groups further confirmed these clinical findings²⁶ and reported that active discopathy could be associated with poor outcomes of LBP, with low rates of return to work, persistent symptoms at 1 year²⁷ and increased back-specific disability.²⁸ No longitudinal observational studies have assessed the correlations between the evolution of pain and evolution of MRI.

Biological signs

Rannou and colleagues also reported an increase in serum level of high-sensitive C-reactive protein in patients with than without chronic LBP and active discopathy (4.64±3.09 mg/L with Modic 1 changes vs 1.33±0.77 mg/L with Modic 0 changes and 1.75±1.30 mg/L with Modic 2 changes).⁹ This observation supports that local inflammation occurs at the vertebral endplate level and is consistent with local cell and tissue activation. Time correlations between Modic modification from 1 to 2 and C-reactive protein evolution have not been studied.

Limits of the concept

Even though the concept of active discopathy could now be defined as a syndrome characterised by DDD associated with MRI, clinical and biological signs of activation, its reality and clinical relevance remain controversial among spine researchers²⁹ and its pathogenesis unclear. How DDD activates and how disc disease activation




Figure 1 Main hypothesised aetiopathogenic mechanisms of intervertebral disc disease activation. DDD, degenerative disc disease; VESB, vertebral endplate subchondral bone.

actually self-limits remains largely unanswered. Even though there are some similarities between osteoarthritis and DDD and between inflammatory flare of peripheral osteoarthritis and active discopathy, we agree that the lack of synovial tissue in spine may differentiate the pathophysiology of these diseases.

WHAT IS THE PRIMER FOR DDD ACTIVATION?

Several factors including adverse biomechanical and biochemical factors may contribute to the activation of DDD, but the onset of active discopathy is most likely multifactorial. Although local inflammation is currently the main therapeutic target, it may be only a late-stage marker of disc disease activation. Other biochemical and metabolic factors, in addition to genetic and biomechanical predisposing factors, could participate in early stages of disc disease activation and be more relevant targets (figure 1).

Adverse personal and environmental factors

The association between active discopathy and polymorphisms of various genes including type 1A1, 9A3 and 11A2 collagens; interleukin-1 α (IL-1 α)³⁰; growth differentiation factor 5; vascular endothelial growth factor; matrix metalloproteinases 3, 9 and 14; a disintegrin and metalloproteinase with thrombospondin motifs 4 and 5; tissue inhibitor of metalloproteinase 3; and vitamin D receptor has been reported.³¹ In a study of 347 twins, the concordance rates of Modic signal were 0.56 in homozygotic twins versus 0.39 in dizygotic twins. The heritability of Modic changes, whatever their type, was estimated at 30% (16%–43%).³² Other adverse personal factors reported to be associated with active discopathy are smoking, overweight and physical work.³³ In an observational cross-sectional study of 100 patients and 500 vertebral levels, Karchevsky and colleagues found Modic changes associated with older age, male gender and increased weight.³⁴ In a retrospective study of 412 patients, Leboeuf-Yde and colleagues reported three independent risk factors for intermittent LBP, DDD or Modic 1 changes on MRI³⁵: smoking ≥ 20 cigarettes/day, overweight and workload. The risk of a Modic 1 signal was maximum when smoking was associated with physical

work (OR=4.6; 95% CI 1.6 to 13.0), then when overweight was associated with physical work (OR=2.9; 95% CI 1.4 to 6.3). Consistently, in 2449 Chinese volunteers, the risk of Modic changes, whatever their type, was increased in smoking and overweight individuals (OR=2.2; 95% CI 1.1 to 4.3). In a recent retrospective study of 16 men and 31 women, Han and colleagues did not confirm the association between smoking and Modic changes but found heavy work and obesity associated more strongly with Modic 3 than other Modic changes.³⁶ Overall, the level of evidence for the above-mentioned clinical associations must be considered low, owing to the cross-sectional or retrospective designs of the studies. No association between other metabolic factors such as diabetes, hypertension, lipid abnormalities and initiation or aggravation of active discopathy has been reported yet.

Adverse biomechanical factors

Inadequate response to mechanical stresses applied to the degenerated intervertebral disc has been suggested to contribute to disc disease activation. DDD results in alterations of the disc biomechanical properties. These biomechanical changes are associated with microfissures or lesions of the vertebral plates adjacent to DDD, increased local expression of proinflammatory molecules such as IL-1 β in animal models^{37,38} and inflammatory and immune responses to the extruded intervertebral disc.³⁹ Consistently, Modic changes are more frequent in L4/L5 and L5/S1 levels than other levels,^{40,41} which suggests that local biomechanical stress may contribute to the distribution of Modic changes. Albert and Manniche⁴² found that the prevalence of Modic 1 changes increased from 9% (17/180 discs) to 29% (48/166 discs) after 14 months of follow-up among patients with chronic LBP and that new Modic changes all developed at the level of a herniated disc. The prevalence of Modic changes was increased in patients who had undergone surgery for lumbar disc herniation (OR=3.5; 95% CI 0.8 to 20.8). In a 3-year prospective study of 60 patients, Modic changes, whatever their type, followed disc herniation in 8/13 cases.²³ The relation between Modic changes and the evolution of disc herniation was further suggested in a prospective study of 30 patients with herniated disc: after 6 months of conservative treatment, the mean reduction in disc herniation volume was -0.326 and -0.152 cm³ for patients without and with Modic changes.⁴³

Adverse biochemical factors

During non-active discopathy

Whether the degree of DDD is associated with disc disease activation is unclear. Some advanced DDDs are not associated with Modic 1 changes, whereas some Modic 1 changes can occur on vertebral endplates adjacent to early-stage DDD and supposedly mechanically competent intervertebral discs. This observation suggests that besides adverse biomechanical factors, other factors such as adverse biochemical factors may be important contributors to disc disease activation. At the molecular

and cellular levels, disc degeneration has been shown to involve several elementary pathways.

Local inflammation with the preponderant role of inflammatory cytokines such as IL-1 β and tumour necrosis factor- α promotes cartilaginous extracellular matrix breakdown but also neovascularisation and neoinnervation within the degenerated discs.^{39–44–48} Innate and adaptive immunity may also participate in intervertebral disc degeneration. The intervertebral disc is the largest avascular organ in the human body and therefore is excluded from immunologic tolerance, contributing to the ‘immune privilege’ of the *nucleus pulposus*. However, the expression of Fas ligand by *nucleus pulposus* cells can stimulate apoptosis of activated Fas-positive cytotoxic T lymphocytes. On the one hand, tears of the *annulus pulposus* will expose the *nucleus pulposus* to the immune system, which will recognise it as a foreign body and will promote activation of the cytotoxic T lymphocytes and the production of immunoglobulins by activated B lymphocytes. On the other hand, the decreased Fas ligand level in the *nucleus pulposus* can lead to an unbalanced immune environment during DDD.^{49–50} In addition, cells of degenerated discs overexpress Toll-like receptors 2 and 4 that can be stimulated by the products of extracellular matrix degradation and amplify the inflammatory and immune response.^{51–52}

Changes in oxidative stress also occur during disc degeneration. Because of its avascular structure, the intervertebral disc is nourished by imbibition from the adjacent cartilaginous and osseous vertebral endplates. Its metabolism is anaerobic and leads to the production of lactates. Local pH is physiologically acidic, between 7.1 for healthy discs and 6.5 or lower for DDD. Acidification of the disc medium is associated with increased apoptosis of disc cells, mainly mediated by abnormal influx of intracellular calcium, and with changes in the disc cell phenotype with increased expression of proinflammatory cytokines such as IL-1 β and IL-6 and factors involved in nociception such as nerve growth and brain-derived neurotrophic factors.^{53–54} In 1969, using a specially constructed antimony pH-electrode needle type, Nachemson reported a negative correlation between pH and disc degeneration, preoperative pain, and the amount of connective tissue reaction around the nerve root in 40 discs from 30 patients who underwent lumbar surgery for ‘rhizopathy’, which suggested that acidification could be a biomarker of painful DDD.⁵⁵ Dimozi and colleagues found that H₂O₂-induced stress on disc cells could promote the upregulation of extracellular matrix-degrading enzymes such as matrix metalloproteinases 1, 2 and 9 and a disintegrin and metalloproteinase with thrombospondin motif 5 and the downregulation of tissue inhibitors of metalloproteinase and aggrecan, the major component of the *nucleus pulposus*.⁵⁶

Changes in lipid metabolism may also contribute to disc degeneration. At the systemic level, hyperlipidaemia promotes lipid peroxidation and the formation of advanced glycation end-products which bind to

extracellular matrix proteins, thereby decreasing its water content. Indirectly, advanced glycation end-products can also stimulate the extracellular matrix degradation by binding to their specific receptor that is expressed by the *nucleus pulposus* cells of the degenerated disc. This binding can lead to an activation of the NLRP3 inflammasome.⁵⁷ Some studies have suggested an association between body mass index and Modic changes. However, none examined the relation between fat distribution and Modic changes. Using MRI and dual energy X-ray absorptiometry in 57 patients with or without LBP, Teichtahl and colleagues found Modic changes associated with increased fat mass index (OR=1.20, 95% CI 1.01 to 1.43). Risk of Modic changes was reduced with gynoid fat (OR=0.62, 95% CI 0.43 to 0.89) but increased with android fat (OR=2.11, 95% CI 1.18 to 3.76), which suggests that Modic changes may be associated with a metabolic component.⁵⁸

Changes in cartilage remodelling involving the cartilaginous vertebral endplates⁵⁹ and chondrocyte-like cells of the intervertebral disc have been described during DDD.⁶⁰ During disc degeneration, phenotypical qualitative and quantitative changes affect cartilaginous vertebral endplates and intervertebral disc cell populations, towards an imbalance between extracellular matrix anabolism and catabolism, with an increased expression of matrix metalloproteinases⁶¹; decreased expression of type II collagen; abnormal expression of type I, III and X collagens; and decreased expression of Sox-9, the key transcription factor of chondrogenesis.⁶² Consistently, increased urinary levels of cartilaginous matrix products of degradation such as type II C-telopeptide are associated with the degree of DDD detected on X-ray.⁶³ A decrease in other extracellular matrix proteins such as aggrecan, versican, biglycan, decorin and fibromodulin in both the *nucleus pulposus* and *annulus fibrosus* has also been reported.⁶⁴

During active discopathy

Even though these above-mentioned elementary pathways can concomitantly be activated during disc degeneration, most DDDs remain non-active. This observation suggests that there may be a continuum between non-active and active discopathies that may rely on individual genetically and environmentally conditioned thresholds separating physiological and pathological pathway activation (figure 2).

The local expression of proinflammatory cytokines, such as tumour necrosis factor- α , is increased in intervertebral discs with than without Modic 1 or 2 changes. Consistently, Tang and colleagues⁶⁵ reported increased expression of some inflammasome components such as NACHT, LRR and PYD domain-containing protein-3, caspase-1 and IL-1 β in the cartilaginous vertebral endplates. Consistently with Crock⁶⁶'s concept of ‘internal disc disruption’,⁶⁷ Ma and colleagues developed the hypothesis that the *nucleus pulposus*, in the absence of normal vascularisation under physiological




Figure 2 Revisiting the concept of internal disc disruption: ‘the nuclear theory’ or *nucleus pulposus* as the primer of local cellular and tissular activation. NSAID, non-steroidal anti-inflammatory drug.

circumstances, can be considered an immune sanctuary. When presented to immune cells of adjacent vertebral plates that will recognise them as powerful antigens, *nucleus pulposus* components trigger an autoimmune and inflammatory cascade and promote subsequent inflammation, neovascularisation and neoinnervation involving adjacent vertebral endplate subchondral bone, detectable as Modic 1 changes on MRI.⁶⁸

Only one study specifically assessed the link between oxidative stress and active discopathy. Belge Kurutas and colleagues reported an increase in oxidative and nitrosative stress markers with an increase in serum levels of nitric acid, 3-nitrotyrosine and malondialdehyde and a decrease in catalase and superoxide dismutase activities in 10 patients with Modic 1 changes as compared with 12 and 10 patients with Modic 2 and 3 changes, respectively.⁶⁹

Some observations have implicated lipid metabolism in disc disease activation. Vertebral bone marrow is rich in adipose tissue in elderly men and at the lower lumbar level. Bone marrow adipose tissue is composed of unsaturated fatty acids and low-density oxidised lipoproteins, capable of activating Toll-like receptors 2 and 4 and maintaining and amplifying inflammatory and immune reactions observed in active discopathy.^{70 71}

Changes in cartilage remodelling have also been described during active discopathy and include decreased expression of chondrogenesis transcription factors such as type 2 collagen and Sox-9.⁶⁵ Cevei and colleagues reported changes in collagen populations depending on Modic 1, 2 or 3 changes, with a decrease in type 1 and 2 collagen levels and an increase in type 3, 4 and 5 levels with Modic 2 changes and a decrease in levels of all collagens and a quasidisappearance of proteoglycan level with Modic 3 changes.¹⁴

Increased local bone remodelling has also been associated with Modic 1 changes. Using histomorphometric

analyses, Perilli and colleagues showed Modic 1 changes associated with greater bone remodelling, Modic 2 changes with decreased remodelling and increased bone formation and Modic 3 changes with osteosclerosis with increased bone formation and decreased bone resorption.⁷² Briggs and colleagues reported no differences in bone mineral density between 11 patients with LBP and Modic 1 changes and 10 healthy controls.⁷³ Intervertebral discs and vertebral endplate bone marrow associated with Modic changes express pro-osteoclastic factors and neurotrophic receptors.⁷⁴ Torkki and colleagues also found increased expression of cytokines involved in osteoclast differentiation and proliferation in intervertebral discs with Modic 1 and 2 changes versus Modic 0 changes.⁷⁵ In a cross-sectional study of 101 patients with lumbar Modic 1 changes, Nguyen and colleagues found in young men that Modic 1 changes were more frequent at L5/S1 level and associated with mild DDD whereas in older women Modic 1 changes were more frequent at the L4/L5 level and associated with advanced DDD, which indicates perhaps a greater involvement of bone remodelling in disc degeneration associated with active discopathy.⁴¹

Finally, some authors suggested that disc disease activation could have an infectious cause, namely discitis with anaerobic germs such *Propionibacterium acnes*.^{76 77} However, this hypothesis has not been confirmed by independent groups.^{78 79}

WHAT ARE THE CLINICAL AND THERAPEUTIC IMPLICATIONS OF THE CONCEPT OF ACTIVE DISCOPATHY?

Clinical implications

The clinical diagnosis of active discopathy is now facilitated by a comprehensive description of clinical and imaging signs associated with this condition, namely a flare of previously unremarkable chronic LBP with discogenic and inflammatory-like features and Modic 1 changes on MRI. When isolated, these clinical and imaging signs lack specificity. The epidemiological association between active discopathy and adverse personal and environmental factors suggests increased risk of developing an active discopathy for some patients with chronic LBP, who therefore may benefit from a specific treatment and follow-up. Most consistently reported adverse personal and environmental factors are overweight, smoking and physical work, but the overall level of evidence is low due to the methodological weakness of the studies. Other important adverse factors may not have been addressed yet.

Finally, LBP is only a symptom. As for any chronic painful condition, patients with chronic LBP may have more than one cause of pain. Even though active discopathy may explain the acute inflammatory component of LBP, it does not address other contributors to chronic pain such as psychological distress, catastrophism, fear-avoidance beliefs, job dissatisfaction, work absenteeism and low educational level. As for any patient with




Figure 3 Towards targeted non-pharmacological and pharmacological treatments in patients with chronic low back pain and active discopathy. IL, interleukin; TNF, tumour necrosis factor.

chronic LBP, these factors should be finely assessed, and modifiable factors concomitantly treated.

Therapeutic implications (figure 3)

As previously described, active discopathy is a multifactorial disease, and different targeted therapeutic approaches have been proposed. Mechanistic approaches aim at combating biomechanical or biochemical adverse factors, whereas structural approaches aim at reversing alterations involving anatomical structures, mostly subchondral bone and intervertebral disc. Both approaches are often combined. However, we have no evidence or practice-based guidelines for the management of active discopathy.

Biomechanical interventions including lumbar bracing,⁸⁰ physical therapy⁸¹ and ultimately lumbar fusion⁷⁸ and biochemical systemic or local interventions including intravenous bisphosphonates^{82–84} or intradiscal therapies with glucocorticoids,^{22 85 86} tumour necrosis factor- α inhibitor,⁸⁷ or IL-6 inhibitor⁸⁸ have been offered. To date, only intradiscal injection of glucocorticoids has shown a short-term but clear clinical benefit on pain in a high-level randomised controlled trial of 135 patients with chronic LBP and active discopathy.¹¹ Physical activity as a specific treatment for patients with chronic LBP and active discopathy has not been assessed. Studies assessing the long-term effects of this type of treatment are needed. In addition, because chronic LBP is only a symptom and concomitant causes may be involved, a multidisciplinary approach is often necessary to obtain sustained positive effects of treatments.

In the past decades, regenerative medicine of the intervertebral disc has raised intense interest. It has involved intradiscal injection of growth factors, with or without plasma-rich platelets, gene therapy or cell grafting (autologous haematopoietic stem cells, mesenchymal stem cells and autologous chondrocytes) to repair the intervertebral disc.^{89–91} The RESPINE project (European Horizon 2020 project ID 732163: REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lumbar SPINE

Box 1 Research agenda

1. Improving the phenotyping of patients with chronic low back pain and active discopathy:

- ▶ Biological phenotyping: serum biomarkers.
- ▶ Imaging phenotyping: radiological biomarkers.
- ▶ Development and validation of classification criteria.

2. Unravelling the pathogenesis of active discopathy activation:

- ▶ In vivo and in vitro modelling of intervertebral disc disease activation.

3. Developing non-pharmacological and pharmacological treatments more efficiently targeting adverse biomechanical, biochemical and environmental factors and taking into account personomics:

- ▶ Tailored to phenotype and predominant adverse factors.
- ▶ Accounting for powerful interactions with adverse social and psychological factors.
- ▶ Aiming to obtain sustained positive effects on pain, function, patient global assessment and returning to work.

unresponsive to conventional therapy) will assess, via a multicentre, randomised, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell-based therapy. However, as previously stated, active discopathy is a whole-organ disease, involving the intervertebral disc and also surrounding anatomical structures. Therefore, the interest of regenerative medicine targeting only the intervertebral disc may be limited. In addition, the benefits of regenerative medicine approaches have not been proven in high-level clinical trials.

CONCLUSIONS AND PERSPECTIVES

DDD is frequent and usually asymptomatic, whereas Modic 1 changes involving the vertebral endplates adjacent to a DDD are associated with inflammatory-like chronic LBP and low-grade local and systemic inflammation, giving rise to the concept of active discopathy. A better understanding of mechanisms underlying disc disease activation and its self-limitation seems of clinical relevance because it could lead to designing more targeted pharmacological and non-pharmacological interventions in the subgroup of patients with chronic LBP and active discopathy (box 1).

Acknowledgements The authors thank Mrs Laura Smales for professional copyediting.

Contributors Conception and design of the study: MB, FR, CN. Drafting of the original protocol: MB, FR, CN. Coordination of the study: CN. Acquisition of data: MB, CN. Obtained funding: CN. Drafting of the present manuscript: MB, CN. Final approval: MB, MMLC, FR, CN.

Funding This study was funded by Assistance Public-Hôpitaux de Paris (Project No MERRI-AAP-2017-008).

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Disease GBD, Injury I, Prevalence C, *et al.* Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1211-59.
2. Jensen RK, Leboeuf-Yde C, Wedderkopp N, *et al.* Is the development of Modic changes associated with clinical symptoms? A 14-month cohort study with MRI. *Eur Spine J* 2012;21:2271-9.
3. Jensen TS, Karppinen J, Sorensen JS, *et al.* Vertebral endplate signal changes (Modic change): a systematic literature review of prevalence and association with non-specific low back pain. *Eur Spine J* 2008;17:1407-22.
4. Modic MT, Masaryk TJ, Ross JS, *et al.* Imaging of degenerative disk disease. *Radiology* 1988;168:177-86.
5. Modic MT, Steinberg PM, Ross JS, *et al.* Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging. *Radiology* 1988;166(1 Pt 1):193-9.
6. Revel M, Poiraudou S, Roux C, *et al.* La discopathie destructrice rapide. *Revue de Médecine Orthopédique* 1990;20:19-22.
7. Revel M. [The concept of discolysis in intervertebral disk disease]. *Acta Reumatol Port* 2006;31:133-40.
8. Revel M, Poiraudou S, Lefèvre-Colau M-M, *et al.* La discopathie destructrice rapide. *Rev Rhum* 2000;67(Suppl 4):266-9.
9. Rannou F, Ouanes W, Boutron I, *et al.* High-sensitivity C-reactive protein in chronic low back pain with vertebral end-plate Modic signal changes. *Arthritis Rheum* 2007;57:1311-5.
10. Nguyen C, Poiraudou S, Rannou F. From Modic 1 vertebral-endplate subchondral bone signal changes detected by MRI to the concept of 'active discopathy'. *Ann Rheum Dis* 2015;74:1488-94.
11. Nguyen C, Boutron I, Baron G, *et al.* Intradiscal Glucocorticoid Injection for Patients With Chronic Low Back Pain Associated With Active Discopathy: A Randomized Trial. *Ann Intern Med* 2017;166:547-56.
12. Nguyen C, Poiraudou S, Rannou F, *et al.* Vertebral subchondral bone. *Osteoporos Int* 2012;23 Suppl 8(Suppl 8):857-60.
13. Rutges JP, Duit RA, Kummer JA, *et al.* A validated new histological classification for intervertebral disc degeneration. *Osteoarthritis Cartilage* 2013;21:2039-47.
14. Cevei M, Roşca E, Liviu L, *et al.* Imagistic and histopathologic concordances in degenerative lesions of intervertebral disks. *Rom J Morphol Embryol* 2011;52(1 Suppl):327-32.
15. Han IB, Ropper AE, Teng YD, *et al.* Association between VEGF and eNOS gene polymorphisms and lumbar disc degeneration in a young Korean population. *Genet Mol Res* 2013;12:2294-305.
16. Binch AL, Cole AA, Breakwell LM, *et al.* Expression and regulation of neurotrophic and angiogenic factors during human intervertebral disc degeneration. *Arthritis Res Ther* 2014;16:416.
17. Krock E, Rosenzweig DH, Chabot-Doré AJ, *et al.* Painful, degenerating intervertebral discs up-regulate neurite sprouting and CGRP through nociceptive factors. *J Cell Mol Med* 2014;18:1213-25.
18. Aoki Y, Nakajima A, Ohtori S, *et al.* Increase of nerve growth factor levels in the human herniated intervertebral disc: can annular rupture trigger discogenic back pain? *Arthritis Res Ther* 2014;16:R159.
19. Pfirrmann CW, Metzendorf A, Zanetti M, *et al.* Magnetic resonance classification of lumbar intervertebral disc degeneration. *Spine* 2001;26:1873-8.
20. Modic MT, Ross JS. Lumbar degenerative disk disease. *Radiology* 2007;245:43-61.
21. Jensen TS, Bendix T, Sorensen JS, *et al.* Characteristics and natural course of vertebral endplate signal (Modic) changes in the Danish general population. *BMC Musculoskelet Disord* 2009;10:81.
22. Nguyen C, Bénichou M, Revel M, *et al.* Association of accelerated switch from vertebral end-plate Modic I to Modic 0 signal changes with clinical benefit of intradiscal corticosteroid injection for chronic low back pain. *Arthritis Rheum* 2011;63:2828-31.
23. Kuisma M, Karppinen J, Niinimäki J, *et al.* A three-year follow-up of lumbar spine endplate (Modic) changes. *Spine* 2006;31:1714-8.
24. Teichtahl AJ, Finnin MA, Wang Y, *et al.* The natural history of Modic changes in a community-based cohort. *Joint Bone Spine* 2017;84:197-202.
25. Nguyen C, Bendeddouche I, Sanchez K, *et al.* Assessment of ankylosing spondylitis criteria in patients with chronic low back pain and vertebral endplate Modic I signal changes. *J Rheumatol* 2010;37:2334-9.
26. Bailly F, Maigne JY, Genevay S, *et al.* Inflammatory pain pattern and pain with lumbar extension associated with Modic 1 changes on MRI: a prospective case-control study of 120 patients. *Eur Spine J* 2014;23:493-7.
27. Jensen OK, Nielsen CV, Sorensen JS, *et al.* Type 1 Modic changes was a significant risk factor for 1-year outcome in sick-listed low back pain patients: a nested cohort study using magnetic resonance imaging of the lumbar spine. *Spine J* 2014;14:2568-81.
28. Määttä JH, Karppinen J, Paananen M, *et al.* Refined Phenotyping of Modic Changes: Imaging Biomarkers of Prolonged Severe Low Back Pain and Disability. *Medicine* 2016;95:e3495.
29. Should Researchers and Journals Be More Cautious in Proposing Novel Pain Conditions? *BackLetter* 2017;32:61-71.
30. Karppinen J, Solovieva S, Luoma K, *et al.* Modic changes and interleukin 1 gene locus polymorphisms in occupational cohort of middle-aged men. *Eur Spine J* 2009;18:1963-70.
31. Martirosyan NL, Patel AA, Carotenuto A, *et al.* Genetic Alterations in Intervertebral Disc Disease. *Front Surg* 2016;3:59.
32. Määttä JH, Kraatari M, Wolber L, *et al.* Vertebral endplate change as a feature of intervertebral disc degeneration: a heritability study. *Eur Spine J* 2014;23:1856-62.
33. Mok FP, Samartzis D, Karppinen J, *et al.* Modic changes of the lumbar spine: prevalence, risk factors, and association with disc degeneration and low back pain in a large-scale population-based cohort. *Spine J* 2016;16:32-41.
34. Karchevsky M, Schweitzer ME, Carrino JA, *et al.* Reactive endplate marrow changes: a systematic morphologic and epidemiologic evaluation. *Skeletal Radiol* 2005;34:125-9.
35. Leboeuf-Yde C, Kjaer P, Bendix T, *et al.* Self-reported hard physical work combined with heavy smoking or overweight may result in so-called Modic changes. *BMC Musculoskelet Disord* 2008;9:5.
36. Han C, Kuang MJ, Ma JX, *et al.* Prevalence of Modic changes in the lumbar vertebrae and their associations with workload, smoking and weight in northern China. *Sci Rep* 2017;7:46341.
37. Albert HB, Kjaer P, Jensen TS, *et al.* Modic changes, possible causes and relation to low back pain. *Med Hypotheses* 2008;70:361-8.
38. McCann MR, Veras MA, Yeung C, *et al.* Whole-body vibration of mice induces progressive degeneration of intervertebral discs associated with increased expression of IL-1 β and multiple matrix degrading enzymes. *Osteoarthritis Cartilage* 2017;25:779-89.
39. Johnson ZI, Schoepflin ZR, Choi H, *et al.* Disc in flames: Roles of TNF- α and IL-1 β in intervertebral disc degeneration. *Eur Cell Mater* 2015;30:104-17.
40. Huang ZY, Xu HC, Lei T, *et al.* The location of Modic changes in the lumbar spine: a meta-analysis. *Eur Spine J* 2016;25:3746-59.
41. Nguyen C, Jousse M, Poiraudou S, *et al.* Intervertebral disc and vertebral endplate subchondral changes associated with Modic 1 changes of the lumbar spine: a cross-sectional study. *BMC Musculoskelet Disord* 2017;18:34.
42. Albert HB, Manniche C. Modic changes following lumbar disc herniation. *Eur Spine J* 2007;16:977-82.
43. Ding L, Teng X, Fan S, *et al.* The Association Between Modic Changes of Lumbar Endplates and Spontaneous Absorption of Herniated Intervertebral Discs. *Cell Biochem Biophys* 2015;71:1357-63.
44. Anderson DG, Tannoury C. Molecular pathogenic factors in symptomatic disc degeneration. *Spine J* 2005;5(6 Suppl):S260-S266.
45. Burke JG, Watson RW, McCormack D, *et al.* Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. *J Bone Joint Surg Br* 2002;84:196-201.
46. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther* 2005;7:R732-45.
47. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1 β and TNF α expression profile. *Arthritis Res Ther* 2007;9:R77.

48. Wang H, Schiltenswolf M, Buchner M. The role of TNF-alpha in patients with chronic low back pain-a prospective comparative longitudinal study. *Clin J Pain* 2008;24:273-8.
49. Satoh K, Konno S, Nishiyama K, et al. Presence and distribution of antigen-antibody complexes in the herniated nucleus pulposus. *Spine* 1999;24:1980-4.
50. Kaneyama S, Nishida K, Takada T, et al. Fas ligand expression on human nucleus pulposus cells decreases with disc degeneration processes. *J Orthop Sci* 2008;13:130-5.
51. Gertzbein SD, Tait JH, Devlin SR. The stimulation of lymphocytes by nucleus pulposus in patients with degenerative disk disease of the lumbar spine. *Clin Orthop Relat Res* 1977;123:149-54.
52. Gertzbein SD. Degenerative disk disease of the lumbar spine: immunological implications. *Clin Orthop Relat Res* 1977;129:68-71.
53. Cuesta A, Del Valle ME, Garcia-Suarez O, et al. Acid-sensing ion channels in healthy and degenerated human intervertebral disc. *Connect Tissue Res* 2014;55:197-204.
54. Gilbert HT, Hodson N, Baird P, et al. Acidic pH promotes intervertebral disc degeneration: Acid-sensing ion channel -3 as a potential therapeutic target. *Sci Rep* 2016;6:37360.
55. Nachemson A. Intradiscal measurements of pH in patients with lumbar rhizopathies. *Acta Orthop Scand* 1969;40:23-42.
56. Dimozi A, Mavrogonatou E, Sklirou A, et al. Oxidative stress inhibits the proliferation, induces premature senescence and promotes a catabolic phenotype in human nucleus pulposus intervertebral disc cells. *Eur Cell Mater* 2015;30:89-103.
57. Song Y, Wang Y, Zhang Y, et al. Advanced glycation end products regulate anabolic and catabolic activities via NLRP3-inflammasome activation in human nucleus pulposus cells. *J Cell Mol Med* 2017;21:1373-87.
58. Teichtahl AJ, Urquhart DM, Wang Y, et al. Modic changes in the lumbar spine and their association with body composition, fat distribution and intervertebral disc height - a 3.0 T-MRI study. *BMC Musculoskelet Disord* 2016;17:92.
59. Farshad-Amacker NA, Hughes A, Herzog RJ, et al. The intervertebral disc, the endplates and the vertebral bone marrow as a unit in the process of degeneration. *Eur Radiol* 2017;27.
60. Kim KW, Chung HN, Ha KY, Ky H, et al. Senescence mechanisms of nucleus pulposus chondrocytes in human intervertebral discs. *Spine J* 2009;9:658-66.
61. Richardson SM, Doyle P, Minogue BM, et al. Increased expression of matrix metalloproteinase-10, nerve growth factor and substance P in the painful degenerate intervertebral disc. *Arthritis Res Ther* 2009;11:R126.
62. Sive JI, Baird P, Jeziorski M, et al. Expression of chondrocyte markers by cells of normal and degenerate intervertebral discs. *Mol Pathol* 2002;55:91-7.
63. Garnerio P, Sornay-Rendu E, Arlot M, et al. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. *Arthritis Rheum* 2004;50:3137-44.
64. Le Maitre CL, Pockert A, Buttle DJ, et al. Matrix synthesis and degradation in human intervertebral disc degeneration. *Biochem Soc Trans* 2007;35(Pt 4):652-5.
65. Tang P, Zhu R, Ji WP, et al. The NLRP3/Caspase-1/Interleukin-1 β Axis Is Active in Human Lumbar Cartilaginous Endplate Degeneration. *Clin Orthop Relat Res* 2016;474:1818-26.
66. Crock HV. Internal disc disruption. A challenge to disc prolapse fifty years on. *Spine* 1986;11:650-3.
67. Chen ZH, Jin SH, Wang MY, et al. Enhanced NLRP3, caspase-1, and IL-1 β levels in degenerate human intervertebral disc and their association with the grades of disc degeneration. *Anat Rec* 2015;298:720-6.
68. Ma XL, Ma JX, Wang T, et al. Possible role of autoimmune reaction in Modic Type I changes. *Med Hypotheses* 2011;76:692-4.
69. Belge Kurutas E, Senoglu M, Yuksel KZ, et al. Oxidative/Nitrosative Stress in Patients With Modic Changes: Preliminary Controlled Study. *Spine* 2015;40:1101-7.
70. Baum T, Yap SP, Karampinos DC, et al. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? *J Magn Reson Imaging* 2012;35:117-24.
71. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. *Mediators Inflamm* 2010;2010:1-21.
72. Perilli E, Parkinson IH, Truong LH, et al. Modic (endplate) changes in the lumbar spine: bone micro-architecture and remodelling. *Eur Spine J* 2015;24:1926-34.
73. Briggs AM, O'Sullivan PB, Foulner D, et al. Vertebral bone mineral measures and psychological wellbeing among individuals with modic changes. *Clin Med Insights Case Rep* 2012;5:CCRep.S9209-41.
74. Dudli S, Sing DC, Hu SS, et al. ISSLS PRIZE IN BASIC SCIENCE 2017: Intervertebral disc/bone marrow cross-talk with Modic changes. *Eur Spine J* 2017;26:1362-73.
75. Torkki M, Majuri ML, Wolff H, et al. Osteoclast activators are elevated in intervertebral disks with Modic changes among patients operated for herniated nucleus pulposus. *Eur Spine J* 2016;25:207-16.
76. Albert HB, Lambert P, Rollason J, et al. Does nuclear tissue infected with bacteria following disc herniations lead to Modic changes in the adjacent vertebrae? *Eur Spine J* 2013;22:690-6.
77. Albert HB, Sorensen JS, Christensen BS, et al. Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy. *Eur Spine J* 2013;22:697-707.
78. Vital JM, Gille O, Pointillart V, et al. Course of Modic 1 six months after lumbar posterior osteosynthesis. *Spine* 2003;28:715-20.
79. Palazzo C, Ferrari M, Lefevre-Colau MM, et al. Lack of effectiveness of antibiotics in chronic low back pain with Modic 1 changes. *Joint Bone Spine* 2017;84.
80. Boutevillain L, Coudeyre E, Giustiniani M, et al. Custom-made rigid lumbar corset can be a short-term pain release option for low back pain patients with Modic 1 active discopathy: A retrospective study. *Ann Phys Rehabil Med* 2017;60:e16.
81. Jensen RK, Leboeuf-Yde C, Wedderkopp N, et al. Rest versus exercise as treatment for patients with low back pain and Modic changes. A randomized controlled clinical trial. *BMC Med* 2012;10:22.
82. Poujol D, Ristori JM, Dubost JJ, et al. Efficacy of pamidronate in erosive degenerative disk disease: A pilot study. *Joint Bone Spine* 2007;74:663-4.
83. Cecchetti S, Pereira B, Roche A, et al. Efficacy and safety of pamidronate in Modic type 1 changes: study protocol for a prospective randomized controlled clinical trial. *Trials* 2014;15:117.
84. Koivisto K, Kyllönen E, Haapea M, et al. Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging. *BMC Musculoskelet Disord* 2014;15:64.
85. Cao P, Jiang L, Zhuang C, et al. Intradiscal injection therapy for degenerative chronic discogenic low back pain with end plate Modic changes. *Spine J* 2011;11:100-6.
86. Beaudreuil J, Dieude P, Poiraudou S, et al. Disabling chronic low back pain with Modic type 1 MRI signal: acute reduction in pain with intradiscal corticotherapy. *Ann Phys Rehabil Med* 2012;55:139-47.
87. Sainoh T, Orita S, Miyagi M, et al. Single Intradiscal Administration of the Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, for Patients with Discogenic Low Back Pain. *Pain Med* 2016;17:40-5.
88. Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. *Spine* 2006;31:2759-66.
89. Pennicooke B, Moriguchi Y, Hussain I, et al. Biological Treatment Approaches for Degenerative Disc Disease: A Review of Clinical Trials and Future Directions. *Cureus* 2016;8:e892.
90. Moriguchi Y, Alimi M, Khair T, et al. Biological Treatment Approaches for Degenerative Disk Disease: A Literature Review of In Vivo Animal and Clinical Data. *Global Spine J* 2016;6:497-518.
91. Basso M, Cavagnaro L, Zanirato A, et al. What is the clinical evidence on regenerative medicine in intervertebral disc degeneration? *Musculoskelet Surg* 2017;101:93-104.